Steris Plc (NYSE:STE) has been assigned an average broker rating score of 1.25 (Strong Buy) from the four analysts that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a buy recommendation and three have assigned a strong buy recommendation to the company.
Brokers have set a twelve-month consensus price target of $100.00 for the company and are predicting that the company will post $1.07 earnings per share for the current quarter, according to Zacks. Zacks has also assigned Steris Plc an industry rank of 168 out of 265 based on the ratings given to related companies.
A number of analysts have recently weighed in on STE shares. BidaskClub downgraded shares of Steris Plc from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Raymond James Financial, Inc. upped their target price on shares of Steris Plc from $90.00 to $95.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 9th. Zacks Investment Research downgraded shares of Steris Plc from a “buy” rating to a “hold” rating in a research report on Tuesday, August 22nd. KeyCorp reaffirmed a “buy” rating and issued a $91.00 target price on shares of Steris Plc in a research report on Tuesday, October 17th. Finally, TD Securities upped their target price on shares of Steris Plc from C$14.00 to C$16.00 and gave the stock a “buy” rating in a research report on Thursday, November 9th.
In related news, Director Richard Martin Steeves sold 156,072 shares of the company’s stock in a transaction dated Friday, September 8th. The shares were sold at an average price of $87.13, for a total value of $13,598,553.36. Following the transaction, the director now owns 9,362 shares in the company, valued at approximately $815,711.06. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP John Adam Zangerle sold 3,650 shares of the company’s stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $88.00, for a total transaction of $321,200.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 192,722 shares of company stock worth $16,913,753. 2.55% of the stock is currently owned by company insiders.
A number of institutional investors have recently made changes to their positions in the stock. State of Wisconsin Investment Board bought a new position in Steris Plc during the 2nd quarter valued at about $1,360,000. The Manufacturers Life Insurance Company lifted its stake in Steris Plc by 1.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 122,520 shares of the medical equipment provider’s stock valued at $9,986,000 after acquiring an additional 1,963 shares during the period. First Trust Advisors LP lifted its stake in Steris Plc by 84.6% during the 2nd quarter. First Trust Advisors LP now owns 15,865 shares of the medical equipment provider’s stock valued at $1,293,000 after acquiring an additional 7,272 shares during the period. Shelton Capital Management bought a new position in Steris Plc during the 2nd quarter valued at about $464,000. Finally, Koch Industries Inc. bought a new position in Steris Plc during the 2nd quarter valued at about $1,089,000. Institutional investors own 93.50% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Zacks: Steris Plc (STE) Given Consensus Rating of “Strong Buy” by Analysts” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2017/11/18/zacks-steris-plc-ste-given-consensus-rating-of-strong-buy-by-analysts.html.
Steris Plc (STE) traded down $0.04 during trading hours on Monday, hitting $87.85. 245,510 shares of the stock were exchanged, compared to its average volume of 471,007. The stock has a market cap of $7,510.00, a P/E ratio of 22.75 and a beta of 1.31. The company has a quick ratio of 2.18, a current ratio of 2.80 and a debt-to-equity ratio of 0.48. Steris Plc has a 12-month low of $64.37 and a 12-month high of $93.39.
Steris Plc (NYSE:STE) last released its earnings results on Wednesday, November 1st. The medical equipment provider reported $0.94 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.95 by ($0.01). The business had revenue of $634.20 million during the quarter, compared to analysts’ expectations of $629.02 million. Steris Plc had a return on equity of 11.49% and a net margin of 5.59%. The firm’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.89 earnings per share. analysts expect that Steris Plc will post 4.06 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 20th. Investors of record on Wednesday, November 22nd will be paid a $0.31 dividend. This represents a $1.24 dividend on an annualized basis and a yield of 1.41%. The ex-dividend date is Tuesday, November 21st. Steris Plc’s payout ratio is 73.81%.
Steris Plc Company Profile
STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.
Get a free copy of the Zacks research report on Steris Plc (STE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Steris Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris Plc and related companies with MarketBeat.com's FREE daily email newsletter.